Giuseppe Giannini Selected Research

Giuseppe Giannini Research Topics

Disease

57	Neoplasms (Cancer) 10/2022 - 02/2002
11	Colorectal Neoplasms (Colorectal Cancer) 02/2022 - 04/2004
9	Carcinoma (Carcinomatosis) 01/2019 - 03/2003
9	Neuroblastoma 01/2018 - 02/2002
6	Breast Neoplasms (Breast Cancer) 12/2020 - 12/2003
6	Ovarian Neoplasms (Ovarian Cancer) 01/2019 - 12/2003
5	Carcinogenesis 06/2021 - 04/2004
5	Neoplasm Metastasis (Metastasis) 12/2018 - 04/2005
4	Microsatellite Instability 01/2022 - 05/2003
3	Colonic Neoplasms (Colon Cancer) 01/2021 - 01/2005
3	Leukemia 07/2007 - 05/2003
2	Medulloblastoma 11/2020 - 11/2019
2	Multiple Myeloma 01/2020 - 01/2016
2	Melanoma (Melanoma, Malignant) 01/2020 - 03/2003
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 07/2018 - 12/2011
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2018 - 03/2015
2	Lung Neoplasms (Lung Cancer) 03/2015 - 01/2015
1	Chromosomal Instability (Chromosome Stability) 01/2022
1	Adenocarcinoma of Lung 01/2021
1	Male Breast Neoplasms (Male Breast Cancer) 08/2019
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2019
1	Triple Negative Breast Neoplasms 01/2019
1	Osteolysis 01/2016
1	Atherosclerosis 01/2016

Drug/Important Bio-Agent (IBA)

9	Proteins (Proteins, Gene)FDA Link 10/2022 - 02/2003
8	heparanaseIBA 12/2020 - 04/2005
5	DNA (Deoxyribonucleic Acid)IBA 12/2020 - 02/2003
5	Histone Deacetylase InhibitorsIBA 01/2019 - 07/2012
5	Pharmaceutical PreparationsIBA 11/2018 - 05/2003
4	Biological ProductsIBA 05/2014 - 11/2005
3	Calcibiotic Root Canal SealerIBA 01/2022 - 01/2005
3	roneparstatIBA 01/2020 - 01/2016
3	Estrogen ReceptorsIBA 01/2019 - 04/2012
3	NucleotidesIBA 01/2019 - 04/2004
3	ErbB Receptors (EGF Receptor)IBA 06/2018 - 12/2003
3	RetinoidsIBA 11/2015 - 02/2002
3	Cisplatin (Platino)FDA LinkGeneric 03/2015 - 07/2005
3	Biomarkers (Surrogate Marker)IBA 10/2014 - 01/2012
3	nutlin 3IBA 01/2012 - 01/2011
3	Tretinoin (Retinoic Acid)FDA LinkGeneric 12/2009 - 02/2002
2	Bevacizumab (Avastin)FDA Link 02/2022 - 01/2013
2	olaparibIBA 10/2021 - 02/2014
2	Cetuximab (Erbitux)FDA Link 01/2021 - 08/2018
2	Hydroxamic Acids (Hydroxamic Acid)IBA 01/2021 - 02/2015
2	LigandsIBA 11/2019 - 01/2006
2	Estrogens (Estrogen)FDA Link 08/2019 - 08/2009
2	Monoclonal AntibodiesIBA 01/2019 - 01/2019
2	Histones (Histone)IBA 01/2019 - 04/2016
2	AvidinIBA 11/2018 - 01/2018
2	CamptothecinIBA 11/2018 - 01/2010
2	AmidesIBA 08/2018 - 01/2010
2	Tyrosine Kinase InhibitorsIBA 06/2018 - 01/2015
2	AnticoagulantsIBA 01/2017 - 01/2016
2	Heparin (Liquaemin)FDA LinkGeneric 01/2017 - 01/2016
2	Integrin alphaVIBA 01/2010 - 01/2006
2	HMGA ProteinsIBA 10/2005 - 09/2005
2	Poly TIBA 12/2004 - 04/2004
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Cell-Free Nucleic AcidsIBA 11/2021
1	MK-8776IBA 10/2021
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2021
1	AntibodiesIBA 01/2021
1	Circulating Tumor DNAIBA 01/2021
1	PolyaminesIBA 12/2020
1	Co-Repressor ProteinsIBA 11/2020
1	Phenformin (Fenformin)IBA 11/2020
1	Therapeutic UsesIBA 11/2020
1	Hypoglycemic Agents (Hypoglycemics)IBA 11/2020
1	BiguanidesIBA 11/2020
1	Hormones (Hormone)IBA 08/2019
1	TenascinIBA 01/2019
1	Caspase 3 (Caspase-3)IBA 01/2019
1	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 01/2019
1	Trastuzumab (Herceptin)FDA Link 01/2019
1	Radioisotopes (Radionuclides)IBA 01/2019
1	EnzymesIBA 01/2019
1	TubulinIBA 01/2019
1	Immunoconjugates (Immunoconjugate)IBA 01/2019
1	ImmunosorbentsIBA 01/2019
1	ST 1481 (Gimatecan)IBA 11/2018
1	PlatinumIBA 07/2018
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018
1	Glycoproteins (Glycoprotein)IBA 01/2018
1	Biotin (Vitamin H)FDA Link 01/2018
1	6- (4- hydroxyphenyl)- 2- thioxo- 2,3- dihydro- 4(1H)- pyrimidinoneIBA 01/2018
1	8-hydroxyguanineIBA 06/2017
1	Reactive Oxygen Species (Oxygen Radicals)IBA 02/2017
1	Oxidants (Oxidizing Agents)IBA 02/2017
1	PeroxiredoxinsIBA 02/2017
1	metaperiodate (periodate)IBA 01/2017
1	BorohydridesIBA 01/2017
1	ChromatinIBA 01/2017
1	Small Interfering RNA (siRNA)IBA 01/2017

Therapy/Procedure

26	Therapeutics 10/2021 - 05/2003
3	Drug Therapy (Chemotherapy) 10/2021 - 01/2013
2	Precision Medicine 06/2021 - 01/2019
2	Combined Modality Therapy 01/2012 - 01/2011
1	Immunotherapy 01/2022
1	Continuity of Patient Care 01/2019
1	Ligation 01/2019